Cargando…

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation

Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. Objectives: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Poletto, Francesco, Spiezia, Luca, Simion, Chiara, Campello, Elena, Dalla Valle, Fabio, Tormene, Daniela, Camporese, Giuseppe, Simioni, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025628/
https://www.ncbi.nlm.nih.gov/pubmed/35458467
http://dx.doi.org/10.3390/v14040737
_version_ 1784690919863222272
author Poletto, Francesco
Spiezia, Luca
Simion, Chiara
Campello, Elena
Dalla Valle, Fabio
Tormene, Daniela
Camporese, Giuseppe
Simioni, Paolo
author_facet Poletto, Francesco
Spiezia, Luca
Simion, Chiara
Campello, Elena
Dalla Valle, Fabio
Tormene, Daniela
Camporese, Giuseppe
Simioni, Paolo
author_sort Poletto, Francesco
collection PubMed
description Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. Objectives: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identify predisposing risk factors in a cohort of hospitalized patients with acute COVID-19 pneumonia undergoing prophylactic-dose heparin. Patients and methods: All consecutive patients admitted for acute COVID-19 pneumonia to the General Internal Medicine Unit of Padova University Hospital, Italy between November 2020 and April 2021, and undergoing prophylactic-dose heparin, were enrolled. Demographic and clinical characteristics and laboratory and radiological findings were recorded on admission. Cases were patients who developed VTE during their hospital stay. Univariable and multivariable logistic regression analyses were used to ascertain the risk factors associated with developing in-hospital VTE. Results: 208 patients (median age: 77 years; M/F 98/110) were included; 37 (18%) developed in-hospital VTE during a median follow-up of 10 days (IQR, 4–18). VTE patients were significantly younger (p = 0.004), more obese (p = 0.002), and had a lower Padua prediction score (p < 0.03) and reduced PaO2/FIO2 ratio (p < 0.03) vs. controls. Radiological findings of bilateral pulmonary infiltrates were significantly more frequent in VTE patients than controls (p = 0.003). Multivariable regression showed that obesity (1.75, 95% CI 1.02–3.36; p = 0.04) and bilateral pulmonary infiltrates on X-rays (2.39, 95% CI 1.22–5.69; p = 0.04) were correlated with increased risk of in-hospital VTE. Conclusions: Obesity and bilateral pulmonary infiltrates on imaging may help clinicians to identify patients admitted to medical wards for acute COVID-19 pneumonia at risk of developing VTE despite prophylactic-dose heparin. Further studies are needed to evaluate whether the administration of therapeutic/intermediate-dose heparin may help prevent VTE episodes without further increasing the bleeding risk.
format Online
Article
Text
id pubmed-9025628
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90256282022-04-23 Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation Poletto, Francesco Spiezia, Luca Simion, Chiara Campello, Elena Dalla Valle, Fabio Tormene, Daniela Camporese, Giuseppe Simioni, Paolo Viruses Article Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. Objectives: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identify predisposing risk factors in a cohort of hospitalized patients with acute COVID-19 pneumonia undergoing prophylactic-dose heparin. Patients and methods: All consecutive patients admitted for acute COVID-19 pneumonia to the General Internal Medicine Unit of Padova University Hospital, Italy between November 2020 and April 2021, and undergoing prophylactic-dose heparin, were enrolled. Demographic and clinical characteristics and laboratory and radiological findings were recorded on admission. Cases were patients who developed VTE during their hospital stay. Univariable and multivariable logistic regression analyses were used to ascertain the risk factors associated with developing in-hospital VTE. Results: 208 patients (median age: 77 years; M/F 98/110) were included; 37 (18%) developed in-hospital VTE during a median follow-up of 10 days (IQR, 4–18). VTE patients were significantly younger (p = 0.004), more obese (p = 0.002), and had a lower Padua prediction score (p < 0.03) and reduced PaO2/FIO2 ratio (p < 0.03) vs. controls. Radiological findings of bilateral pulmonary infiltrates were significantly more frequent in VTE patients than controls (p = 0.003). Multivariable regression showed that obesity (1.75, 95% CI 1.02–3.36; p = 0.04) and bilateral pulmonary infiltrates on X-rays (2.39, 95% CI 1.22–5.69; p = 0.04) were correlated with increased risk of in-hospital VTE. Conclusions: Obesity and bilateral pulmonary infiltrates on imaging may help clinicians to identify patients admitted to medical wards for acute COVID-19 pneumonia at risk of developing VTE despite prophylactic-dose heparin. Further studies are needed to evaluate whether the administration of therapeutic/intermediate-dose heparin may help prevent VTE episodes without further increasing the bleeding risk. MDPI 2022-03-31 /pmc/articles/PMC9025628/ /pubmed/35458467 http://dx.doi.org/10.3390/v14040737 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Poletto, Francesco
Spiezia, Luca
Simion, Chiara
Campello, Elena
Dalla Valle, Fabio
Tormene, Daniela
Camporese, Giuseppe
Simioni, Paolo
Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
title Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
title_full Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
title_fullStr Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
title_full_unstemmed Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
title_short Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
title_sort risk factors of venous thromboembolism in noncritically ill patients hospitalized for acute covid-19 pneumonia receiving prophylactic-dose anticoagulation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025628/
https://www.ncbi.nlm.nih.gov/pubmed/35458467
http://dx.doi.org/10.3390/v14040737
work_keys_str_mv AT polettofrancesco riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT spiezialuca riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT simionchiara riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT campelloelena riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT dallavallefabio riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT tormenedaniela riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT camporesegiuseppe riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation
AT simionipaolo riskfactorsofvenousthromboembolisminnoncriticallyillpatientshospitalizedforacutecovid19pneumoniareceivingprophylacticdoseanticoagulation